CLINICAL & PIPELINE·Clinical Trial Termination
Hoffmann-La Roche Halts Idasanutlin Phase Ib/II Trial for Acute Myeloid Leukemia Due to Strategic Re-prioritization
Hoffmann-La Roche has terminated its Phase Ib/II clinical trial (NCT03850535) for Idasanutlin in Acute Myeloid Leukemia (AML). This decision, effective June 2022, was driven by an 'overall company strategy about the adult AML' rather than safety concerns. This signals a significant re-prioritization within Roche's oncology pipeline, impacting future development and API procurement for Idasanutlin.
90-Day Activity